Pathophysiology of MI

Edit Answers
123456789101112131415161718192021222324
Across
  1. 3. monocyte chemotactic protein 1
  2. 5. bridging molecule
  3. 7. product of the mavelonate pathway
  4. 11. clotting pathway initiated by contact with glass
  5. 12. inhibits cyclooxygenase
  6. 14. clotting pathway initiated by tissue damage
  7. 15. reduces the bioavailability of nitric oxide
  8. 16. cGMP can produce this effect in blood vessels
  9. 19. P2X antagonist that inhibits ADP-induced platelet aggregation
  10. 20. converts soluble fibrinogen to insoluble strands of fibrin
  11. 23. inhibitor of NOS
  12. 24. inactive precursor of proteolytic enzyme
Down
  1. 1. the principal matrix protein that interacts with platelets
  2. 2. describes platelets that have not been activated
  3. 4. factor II
  4. 6. end product of the coagulation pathway
  5. 8. inhibit the rate-limiting enzyme for cholesterol biosynthesis
  6. 9. reduces platelet aggregation by inhibiting PDE, blocking adenosine uptake into red cells, and reduces TXA2 synthesis
  7. 10. two thirds of the body's cholesterol is synthesised here
  8. 13. maintains platelets inactive state by releasing PGI2 and NO
  9. 17. substrate for nitric oxide synthase
  10. 18. activates guanylyl cyclase, which converts GTP to cyclic GMP
  11. 21. a natural anticoagulant
  12. 22. vascular cell adhesion molecule 1